NextCure, Inc. (NXTC) · Nov 20, 2026 · Delisting

NextCure delisting notice puts its merger on the clock

Nasdaq deficiency — $5.503M equity vs $10.0M minimum; compliance-plan deadline January 4, 2027

NextCure’s delisting notice has no immediate trading impact, but the Avere merger must close before January 4 to address the equity shortfall.

NextCure is no longer primarily a clinical-stage oncology developer: it has wound down much of its legacy pipeline and is using the proposed Avere merger to pivot toward Avere’s oral IL-23 inflammatory-disease programs. The latest quarterly filing had already disclosed that equity was below Nasdaq’s minimum, so this 8-K formalizes a known vulnerability rather than creating a surprise.

The filing adds a real listing risk, but not an immediate delisting. Nasdaq says NextCure’s stockholders’ equity was $5.503 million against a $10.0 million requirement, and the company failed the alternative market-value and assets/revenue tests.

Measure (Item 3.01)As reportedRequirementDeadline
Stockholders’ equity$5.503M$10.0M minimum—
Compliance-plan window45 days—January 4, 2027

The merger is now more than a strategic pivot—it is the practical compliance solution. NextCure expects the Avere transaction to close in mid-December, before the January 4 grace-period deadline, and says completion would likely restore compliance. But that outcome remains conditional on stockholder approval and other closing requirements; if the merger slips, NextCure must submit a remediation plan and still cannot assure Nasdaq compliance.

The immediate damage is contained, while the dependency is clearer. Trading continues on Nasdaq for now, so this is not a present delisting event. But it exposes how little standalone balance-sheet flexibility remains and makes timely completion of the already-public merger more important to the company’s near-term continuity. 〔0〕

Bottom line: This is a modest negative development, not a change in the merger thesis: the equity deficiency was already known, but Nasdaq has now put a firm compliance clock around it. The Avere closing is effectively the company’s near-term answer to the listing problem.

What to watch next

NextCure stockholder vote on Avere merger, December 9

Original filing on SEC EDGAR

More NextCure, Inc. news

NextCure delisting notice puts its merger on the clock | NXTC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.